Evaluating Drug Resistant Mutations to HCV NS3 Protease Inhibitors in Iranian Naïve Patients
- 4 Downloads
Hepatitis C virus (HCV) is an important causative agent of acute and chronic hepatitis. The non-structural protein 3 (NS3) of HCV retains two enzymatic domains which are essential for the virus life cycle. The serine protease inhibitors have developed to improve the responses of HCV-infected patients that have an effective impact on NS3. Nonetheless, drug-resistant variants are the prominent obstruction toward therapeutic success. Sixty-eight Iranian patients infected with HCV genotypes 1a and 3a and diagnosed with chronic active hepatitis were examined. Plasma viral RNA was used to amplify and sequence the HCV NS3 gene; also, HCV viral load, molecular genotyping, and the ALT test were determined for all samples. The sequencing results were used to be analyzed by several reliable bioinformatics tools to determine the physicochemical properties, B cell epitopes, post-modification changes and secondary/tertiary structures; and evaluate the interactions with four drugs. Our results showed that 45% of patients were 1a genotype, the rest of them belonged to 3a genotype, and 70% of patients had abnormal ALT and AST levels. Several substitutions were observed in codons I52M, S102A, L132I, and S166A in 3a genotype and 40, 153 and 91 in 1a genotype. Interactions between references and sample sequences with available drugs showed that different genotypes or common mutations could not have any striking effect on the energy value of the interaction. This study displayed resistance mutations and genetic polymorphisms of NS3 region that are crucial in determining the efficiency of protease inhibitor class of drugs in Iranian HCV infected patients.
KeywordsHCV NS3 Drug resistance Bioinformatics
Hepatitis C virus
Non-structural protein 3
Iran hepatitis network
RNA-dependent RNA polymerase
Human immunodeficiency virus
Hepatitis B surface antigen
The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran and Shariati Hospital, Dr. Shahin Merat, professor of gastrology and hepatology at Tehran University of Medical Sciences for providing us with absolute opportunity to be in touch with his patients, also Tehran University of Medical Sciences personnel for sampling, and Center for Development of Clinical Research of Nemazee Hospital and Dr. Nasrin Shokrpour for editorial assistance.
This study was funded by Shiraz University of Medical Sciences (Grant Number 94-01-01-9218).
Compliance with Ethical Standards
Conflict of interest
All authors declare that they have no conflict of interest.
This article does not contain any studies with animals performed by any of the authors.
- Afrasiabi M, Hosseini SY, Yaghobi R, Fattahi MR, Ardebili M, Khodadad M (2015) Analysis of naturally occurring resistant mutations to hepatitis C virus NS3 protease inhibitors: a preliminary study in South of Iran. Jundishapur J Microbiol 8Google Scholar
- Alavian SM, Hajarizadeh B, Lankarani KB, Sharafi H, Daryani NE, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H, Nikbin M (2016) Recommendations for the clinical management of hepatitis C in Iran: a consensus-based national guideline. Hepat Mon 16Google Scholar
- Costantino A, Spada E, Equestre M, Bruni R, Tritarelli E, Coppola N, Sagnelli C, Sagnelli E, Ciccaglione AR (2015) Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. Virol J 12:186PubMedPubMedCentralCrossRefGoogle Scholar
- Dehghani B, Hashempour T, Hasanshahi Z (2019b) Using immunoinformatics and structural approaches to design a novel HHV8 vaccine. Int J Pept Res Ther 1–11Google Scholar
- Dehghani B, Hashempour T, Hasanshahi Z, Moayedi J (2019c) Bioinformatics analysis of domain 1 of HCV-core protein: Iran. Int J Pept Res Ther 1–18Google Scholar
- Gupta R, Jung E, Brunak S (2017) Prediction of N-glycosylation sites in human proteins 2004. http://www.cbs.dtu.dk/services/NetNGlyc
- Hashempoor T, Alborzi AM, Moayedi J, Ajorloo M, Bamdad T, Sharifi AH, Lavergne JP, Haj-sheykholeslami A, Merat S (2018) A decline in anti-core + 1 antibody titer occurs in successful treatment of patients infected with hepatitis C virus. Jundishapur J Microbiol 11Google Scholar
- Hoffmann L, Faffe DS, Lima JFC, Capitanio TA, Cabral BCA, Ürményi TP, Coelho HSM, Rondinelli E, Villela-Nogueira CA, Silva R (2015) No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy. BBA Clin 3:146–151PubMedPubMedCentralCrossRefGoogle Scholar
- Nishiya AS, de Almeida-Neto C, Ferreira SC, Alencar CS, Di-Lorenzo-Oliveira C, Levi JE, Salles NA, Jr AM, Sabino EC (2014) HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in Sao Paulo, Brazil. PLoS ONE 9:e86413PubMedPubMedCentralCrossRefGoogle Scholar
- Patel K, Pauli M, Abdelghany S (2011) Telaprevir: a novel, protease inhibitor for the treatment of hepatitis C virus. Formulary 46:205–213Google Scholar
- Raj VS, Hundie GB, Schürch AC, Smits SL, Pas SD, Le Pogam S, Janssen HL, de Knegt RJ, Osterhaus AD, Najera I, Boucher CA (2017) Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment naïve patients. Sci Rep 7Google Scholar
- Rajagopalan R, Pan L, Schaefer C, Nicholas J, Lim S, Misialek S, Stevens S, Hooi L, Aleskovski N, Ruhrmund D (2017) Preclinical characterization and human microdose pharmacokinetics of ITMN-8187, a nonmacrocyclic inhibitor of the hepatitis C virus NS3 protease. Antimicrob Agents Chemother 61:e01569-16PubMedCrossRefGoogle Scholar
- Saadoun D, Rigon MR, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D (2013) Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2012–202770Google Scholar
- Saha S, Raghava GPS (2004) BcePred: prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. In: International conference on artificial immune systems. Springer, New York, 197–204Google Scholar
- Tan S-L (2006) Hepatitis C viruses: genomes and molecular biology. Horizon Scientific Press, PooleGoogle Scholar
- Wilby KJ, Partovi N, Ford J-AE, Greanya ED, Yoshida EM (2012) Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol Hepatol 26:205–210Google Scholar
- World Health Organization (2017) Global hepatitis report 2017. World Health Organization, GenevaGoogle Scholar
- Xue W, Ban Y, Liu H, Yao X (2013) Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. J Chem Inf Model 54:621–633PubMedCrossRefPubMedCentralGoogle Scholar
- Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Gupta S, Deckman D, Fellows K, Hussain M, Cutler DL (2005) Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-alpha). Hepatology 42:233A-34AGoogle Scholar